Rare disease

UK
#BioIndustry Association #European Federation of Pharmaceutical Industries and Associations #Rare disease #UK

UK lags behind on access to treatments for rare diseases

The UK lags comparable countries, including France and Germany, on the degree of availability of treatments for rare diseases, according to a new report. The report by the BIA and consultancy firm PwC has highlighted the progress that has been made in improving access to rare… Read More

#News

Doctor points at child's brain scan
#Francis Crick Institute #Gene therapy #Great Ormond Street Hospital #Paediatrics #Rare disease

Researchers design genetic therapy to prevent brain deterioration

A research team at the Francis Crick Institute and Great Ormond Street Hospital (GOSH)/UCL Great Ormond Street Institute of Child Health have identified potential treatments for children with rare genetic conditions. The researchers have shown that problems with calcium underlie these progressive diseases. Stabilising calcium levels… Read More

#Editor's Choice #News

FDA approval
#Biologics #FDA #Rare disease #Rocket Pharmaceuticals

FDA acceptance advances investigational gene therapy 

The US Food and Drug Administration (FDA) has accepted Rocket Pharmaceuticals’ Biologics License Application (BLA) and granted Priority Review for RP-L201 (marnetegragene autotemcel).  Rocket Pharmaceuticals is a late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need. RP-L201 is a lentiviral vector… Read More

#News #Regulatory

#Drug approvals #FDA #Oncology #Rare disease

Positive data for 4SC’s CTCL treatment fuels marketing strategy  

Biotech company 4SC has announced positive new data for its treatment for patients with advanced-stage cutaneous T-cell lymphoma (CTCL).  Findings from the RESMAIN study of 4SC’s resminostat (Kinselby) treatment show that the therapy can postpone disease progression in advanced CTCL. The RESMAIN study is one of… Read More

#News

The European Medicines Agency building
#EFPIA #Europe #Orphan drugs #Pharmaceuticals #Rare disease #Regulatory

Proposed changes to EU regulation risks progress on orphan drugs

Plans to overhaul the EU regulation on rare disease therapies risk undermining two decades of progress, a new report claims. The assessment, commissioned by the European Federation of Pharmaceutical Industries and Associations (EFPIA), was conducted by Dolon, a strategic consultancy specialising in rare diseases. The European Orphan Medicinal Product Regulation… Read More

#News #Regulatory

FDA headquarters
#Biologics / Biotechnology #FDA #Rare disease #Regulatory

FDA pilot programme to boost rare disease therapies

The US Food and Drug Administration (FDA) has announced a pilot programme with the aim of accelerating the development of novel drug and biological products for rare diseases. The agency is inviting a limited number of sponsors to participate in the programme, which allows for more frequent communication with FDA… Read More

#News #Regulatory

Stamp of approval
#Chiesi #National Institute for Health and Care Excellence (NICE) #Rare disease #UK

NICE recommends enzyme therapy for Fabry disease

The UK’s National Institute for Health and Care Excellence (NICE) has recommended Elfabrio (pegunigalsidase alfa) as an option for treating Fabry disease (or alpha-galactosidase deficiency). The drug is recommended for use on the NHS under the terms of a confidential commercial agreement. Pegunigalsidase alfa is a novel enzyme replacement therapy… Read More

#News #Regulatory

Hormones in the brain concept
#ALS #Bloom Science #Clinical trial #Phase I trial #Rare disease

Early trial success for Dravet syndrome and ALS therapeutic

Bloom Science has announced positive topline data from a Phase I clinical trial of BL-001, a potential first-in-class therapeutic the company is developing for Dravet syndrome and amyotrophic lateral sclerosis (ALS). In the trial, BL-001 demonstrated a favourable safety profile and was well… Read More

#News

#FDA #Ipsen #Phase III trial #Rare disease #Regulatory

FDA approves first treatment for rare connective tissue disorder

Ipsen’s Sohonos (palovarotene) has become the first drug approved for patients with fibrodysplasia ossificans progressiva (FOP) in the US, following the granting of a marketing authorisation by the Food and Drug Administration (FDA). The capsules are approved for reduction in the volume of new heterotopic ossification (extra-skeletal bone formation) in… Read More

#News #Regulatory

AI and genomics
#AI / data analytics / healthtech / informatics #DNA #Genetics / genomes #Precision medicine #Rare disease

New podcast on the future for genomics and big data

This is the latest episode of the free DDW narrated podcast, “What lies in the future for genomics and big data?”, which covers two articles written for Volume 23, Issue 3 – Summer 2022 of DDW. They are called “What’s the next step in big… Read More

#News

Heart attack patient with doctor
#ARMGO Pharma #Cardiovascular disease #Heart disease #Phase II trial #Rare disease

Trials of new drug for rare genetic heart disease enter Phase II

ARMGO Pharma has enrolled the first patient in a Phase II proof-of-concept clinical trial using its Rycal ARM210 (also known as S48168), for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT). The trial, performed at the Amsterdam University Medical Center (Amsterdam UMC), Netherlands and the Mayo… Read More

#News

Drug discovery illustration
#Covid-19 #Drug repositioning #Drug repurposing #Events #Paediatrics #Pharmacology #Rare disease #World Congress of Basic & Clinical Pharmacology

Drug repurposing: The benefits, risks and what we learned from Covid-19

What are benefits of drug repurposing and why do clinical drug trials so often fail? Diana Spencer summarises the key messages from the ‘Drug Repurposing: Challenges and Opportunities’ Symposium held at the 19th World Congress of Basic & Clinical Pharmacology (WCP) 2023. The Drug Repurposing symposium at WCP 2023 was… Read More

#Exclusive Content

Female scientist
#AI / data analytics / healthtech / informatics #BC Platforms #Rare disease #Real world data

Harnessing real-world data for rare and orphan disease research

This paid-for advertorial by BC Platforms appeared in DDW Volume 24 – Issue 3, Summer 2023 The use of real-world data (RWD) is demonstrating significant potential to enhance rare and orphan disease clinical research and development. By incorporating data from sources such as electronic health records, medical claims, patient registries, and… Read More

#Exclusive Content

Research in genetics laboratory
#Advanced Therapy Medicinal Products (ATMPs) #Alliance for Regenerative Medicine #Cell and gene therapy #Europe #Rare disease

Proposed EU clinical assessment rules would reject ATMPs

The proposed joint clinical assessment methodology would have rejected nearly 90% of the ATMPs currently authorised in the EU, claims the Alliance for Regenerative Medicine (ARM). According to ARM, all seven gene therapies for rare genetic diseases would have been rejected under the baseline methodologies proposed… Read More

#Editor's Choice #News

#FDA #Minoryx Therapeutics #Neurodegenerative disorders #Phase III trial #Rare disease

FDA approves Phase III cerebral Adrenoleukodystrophy trial

The US Food and Drug Administration (FDA) has approved Minoryx Therapeutics’ Phase III clinical trial (CALYX) of leriglitazone, to treat adult male X-linked Adrenoleukodystrophy (X-ALD) patients with cerebral Adrenoleukodystrophy (cALD). Patient recruitment is expected to start by the end of Q2 2023 with results anticipated by late 2025. Marc Martinell,… Read More

#News #Regulatory

siRNA
#DTx Pharma #FDA #Orphan drugs #Rare disease #siRNA

siRNA therapy for rare disease granted orphan status

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation to DTx Pharma’s DTx-1252, an investigational small interfering RNA (siRNA) therapeutic for the treatment of Charcot-Marie-Tooth Disease Type 1A (CMT1A). CMT1A is a progressive, neuromuscular, autosomal-dominant disease that leads to life-long loss of muscle… Read More

#News